WallStreetZenWallStreetZen

NASDAQ: BXRX
Baudax Bio Inc Stock

$3.40+0.12 (+3.66%)
Updated Feb 3, 2023
BXRX Price
$3.40
Fair Value Price
$30,537.73
Market Cap
$1.70M
52 Week Low
$1.55
52 Week High
$291.06
P/E
0.01x
P/B
-0.09x
P/S
2.14x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.36M
Earnings
-$20.11M
Gross Margin
-105.4%
Operating Margin
-1,309.41%
Profit Margin
-1,656.8%
Debt to Equity
-1.9
Operating Cash Flow
-$37M
Beta
0.84
Next Earnings
Mar 14, 2023
Ex-Dividend
N/A
Next Dividend
N/A

BXRX Overview

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BXRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

BXRX ($3.40) is undervalued by 99.99% relative to our estimate of its Fair Value price of $30,537.73 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
BXRX ($3.40) is significantly undervalued by 99.99% relative to our estimate of its Fair Value price of $30,537.73 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
BXRX is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BXRX due diligence checks available for Premium users.

Be the first to know about important BXRX news, forecast changes, insider trades & much more!

BXRX News

Valuation

BXRX fair value

Fair Value of BXRX stock based on Discounted Cash Flow (DCF)
Price
$3.40
Fair Value
$30,537.73
Undervalued by
99.99%
BXRX ($3.40) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BXRX ($3.40) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BXRX is forecast by analysts... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

BXRX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
0.01x
Industry
10.7x
Market
15.09x
BXRX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BXRX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

BXRX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-0.09x
Industry
5.11x

BXRX's financial health

Profit margin

Revenue
$238.0k
Net Income
-$29.2M
Profit Margin
-12,271%
BXRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BXRX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$17.5M
Liabilities
$37.1M
Debt to equity
-1.9
BXRX's short-term liabilities ($21.28M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BXRX's long-term liabilities ($15.78M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BXRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BXRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$3.9M
Investing
$0.0
Financing
$4.3M
BXRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

BXRX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
BXRX$1.70M+3.66%0.01x-0.09x
ENSC$2.03M-8.57%-0.04x-0.33x
INM$2.06M+5.77%-0.07x0.19x
ALLR$2.43M-9.20%-0.05x1.68x
CALA$875.75k-50.68%-0.01x0.03x

Baudax Bio Stock FAQ

What is Baudax Bio's quote symbol?

NASDAQ: BXRX) Baudax Bio trades on the NASDAQ under the ticker symbol BXRX. Baudax Bio stock quotes can also be displayed as NASDAQ: BXRX.

If you're new to stock investing, here's how to buy Baudax Bio stock.

What is the 52 week high and low for Baudax Bio (NASDAQ: BXRX)?

(NASDAQ: BXRX) Baudax Bio's 52-week high was $291.06, and its 52-week low was $1.55. It is currently -98.83% from its 52-week high and 119.35% from its 52-week low.

How much is Baudax Bio stock worth today?

(NASDAQ: BXRX) Baudax Bio currently has 500,094 outstanding shares. With Baudax Bio stock trading at $3.40 per share, the total value of Baudax Bio stock (market capitalization) is $1.70M.

Baudax Bio stock was originally listed at a price of $9,800.01 in Nov 14, 2019. If you had invested in Baudax Bio stock at $9,800.01, your return over the last 3 years would have been -99.97%, for an annualized return of -92.97% (not including any dividends or dividend reinvestments).

How much is Baudax Bio's stock price per share?

(NASDAQ: BXRX) Baudax Bio stock price per share is $3.40 today (as of Feb 3, 2023).

What is Baudax Bio's Market Cap?

(NASDAQ: BXRX) Baudax Bio's market cap is $1.70M, as of Feb 7, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Baudax Bio's market cap is calculated by multiplying BXRX's current stock price of $3.40 by BXRX's total outstanding shares of 500,094.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.